Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of oral covalent small-molecule drugs for treating metabolic diseases, with a primary focus on diabetes and obesity. Its lead product candidate, icovamenib, is an orally bioavailable, potent, and selective covalent inhibitor of menin, a scaffold protein involved in histone modification and epigenetic gene regulation that influences cell cycle control, apoptosis, and DNA damage repair. Icovamenib is being evaluated in clinical studies such as COVALENT-111 and COVALENT-121 for type 2 diabetes, demonstrating potential in glycemic control and benefits for insulin-deficient patient populations. The company is also advancing BMF-650, a next-generation oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist, which shows promise in preclinical models for weight loss, appetite suppression, and glycemic improvement in obesity and related disorders. Biomea Fusion employs its proprietary FUSION System discovery platform to build a pipeline targeting these high-need areas in the metabolic disease landscape. Founded in 2017 and headquartered in San Carlos, California, the company operates exclusively in the biopharmaceutical sector, emphasizing innovative oral therapies to address unmet needs in diabetes and obesity management.